Floatz logo

LISPRO-PH20 COMPONENT RHUPH20

Urothelial Carcinoma

Bristol-Myers Squibbprotein_peptidePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

166 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

LISPRO-PH20 COMPONENT RHUPH20 is also rated in:

hereditary angioedemaDormant
B
Indicative ·
62 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
59 / 100
View asset →
melanomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →